Drug Safety

, Volume 37, Issue 6, pp 459–464

The 8th International Congress on Cutaneous Adverse Drug Reactions, Taiwan, 2013: Focus on Severe Cutaneous Adverse Reactions

  • Roni P. Dodiuk-Gad
  • Wen-Hung Chung
  • Chih-Hsun Yang
  • Chun-Wei Lu
  • Rosaline Chung-Yee Hui
  • Neil H. Shear
Meeting Report


  1. 1.
    Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000;119:225–30.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14:1343–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Roujeau JC, Bricard G, Nicolas JF. Drug-induced epidermal necrolysis: important new piece to end the puzzle. J Allergy Clin Immunol. 2011;128:1277–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Brockow K, Romano A. Skin tests in the diagnosis of drug hypersensitivity reactions. Curr Pharm Des. 2008;14:2778–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Kano Y, Inaoka M, Sakuma K, Shiohara T. Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome. Toxicology. 2005;209:165–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Kang S, Cho S, Chung JH, Hammerberg C, Fisher GJ, Voorhees JJ. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol. 2005;166:1691–9.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–79.PubMedCrossRefGoogle Scholar
  8. 8.
    Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci U S A. 2012;109:9959–64.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Rive CM, Bourke J, Phillips EJ. Testing for drug hypersensitivity syndromes. Clin Biochem Rev. 2013;34:15–38.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Vocanson M, Achachi A, Mutez V, Cluzel-Tailhardat M, Varlet BL, Rozières A, et al. Human T cell priming assay: depletion of peripheral blood lymphocytes in CD25(+) cells improves the in vitro detection of weak allergen-specific T cells. EXS. 2014;104:89–100.PubMedGoogle Scholar
  11. 11.
    Pichler WJ. The p-i Concept: pharmacological interaction of drugs with immune receptors. World Allergy Organ J. 2008;1:96–102.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88:60–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, et al.; RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133(5):1197–204.Google Scholar
  14. 14.
    Niihara H, Kakamu T, Fujita Y, Kaneko S, Morita E. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. J Dermatol. 2012;39:594–601.PubMedCrossRefGoogle Scholar
  15. 15.
    Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.PubMedCrossRefGoogle Scholar
  16. 16.
    Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134–9.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Ushigome Y, Kano Y, Hirahara K, Shiohara T. Human herpesvirus 6 reactivation in drug-induced hypersensitivity syndrome and DRESS validation score. Am J Med. 2012;125:e9–10.PubMedCrossRefGoogle Scholar
  18. 18.
    Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol. 2009;182:8071–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Criado PR, Criado RF, Avancini Jde M, Santi CG. Drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS): a review of current concepts. An Bras Dermatol. 2012;87:435–49.Google Scholar
  20. 20.
    Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2013;68:721–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Roni P. Dodiuk-Gad
    • 1
    • 2
  • Wen-Hung Chung
    • 3
    • 4
  • Chih-Hsun Yang
    • 3
    • 4
  • Chun-Wei Lu
    • 3
    • 4
  • Rosaline Chung-Yee Hui
    • 3
    • 4
  • Neil H. Shear
    • 1
    • 5
  1. 1.Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences CentreUniversity of TorontoTorontoCanada
  2. 2.Department of DermatologyHa’emek Medical CenterAfulaIsrael
  3. 3.Department of Dermatology, Drug Hypersensitivity Clinical and Research CenterChang Gung Memorial HospitalsTaipei, Linkou, and KeelungTaiwan
  4. 4.College of MedicineChang Gung UniversityTaoyuanTaiwan
  5. 5.Division of Clinical Pharmacology and Toxicology, at Sunnybrook, Department of Medicine, Sunnybrook Health Sciences CentreUniversity of TorontoTorontoCanada

Personalised recommendations